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The Missing Bone Minireview
Gideon A. Rodan and Shun-ichi Harada that leads tosequential expression of other transcription
factors and of phenotype-specific genes (Rawls andDepartment of Bone Biology and Osteoporosis
Research Olson, 1997). Homology searches for HLH factors that
play a similar role in adipocyte, osteoblast, or chon-Merck Research Laboratories
West Point, Pennsylvania 19486 droblast differentiation have not been successful (nega-
tive data are rarely published). However, a key regulatory
transcription factor in adipocyte differentiation, belong-
ing to the nuclear receptor family (peroxisome prolifera-The mineralized skeleton was essential for the evolution
tor activated receptor g2 or PPARg2; Tontonoz et al.,of terrestrial vertebrates since it provided an ample
1994), was discovered three years ago. A transcriptionsource of calcium and phosphate and facilitated loco-
factor that plays a key role in osteoblast differentiationmotion on solid ground. Bone also provides protection
is described in this issue of Cell. This factor is CBFA1,from external injury for the brain and spinal cord. In
a member of the core-binding factor family, also knownaddition, it houses and interacts with the bone marrow,
as PEBP2aA (for polyoma enhancerbinding protein) andsupporting hematopoieses. Another crucial mechanical
as AML3 (for acute myeloid leukemia).function of bone in land vertebrates is breathing, and
CBFA belongs to the Runt domain gene family, homol-a severely compromised skeleton causes immediate
ogous to the Drosophila melanogoster pair-rule genepostnatal death.
runt that plays a role in the formation of the segmentedEmbryologically, we recognize two types of bone. In-
body pattern as well as in sex determination and intramembraneous bone is formed directly by bone cells
the development of the nervous system (Ogawa et al.,within connective tissue. It originates from the branchial
1993). The a subunitof theseheterodimeric transcriptionarches and gives rise to the bones of the skull and the
factors binds to DNA via the Runt domain when pairedface. The rest of the skeleton is generated by bone
with the b subunit, called CBFB/PEBP2b, which doesreplacement of a cartilage anlage through the process
not directly interact with DNA. The consensus DNAbind-of endochondral ossification, where vascular invasion
ing sequence is PuACCPuCA, originally identified as anis followed by the deposition of bone on mineralized
enhancer in polyoma virus and murine leukemia virus,cartilage, which is subsequently removed. This bone is
but also present in many T cell±specific genes, TCRa,derived from the somites that contain multipotent cells
-b, -d, -g, CD3e, as well as in genes encoding the en-capable of differentiating into muscle, dermis, and carti-
zymes myeloperoxidase, neutrophil elastase, and gran-lage. Experimental approaches have identified pluripo-
zyme B, and in several genes encoding cytokines andtent mesenchymal cells that have myogenic, chondro-
their receptors GM-CSF, IL-3, and CSF-1.genic, and adipogenic potential, raising the question of
Three CBFA genes have been identified: CBFA1/signals and regulatory pathways that determine commit-
PEBP2aA/AML3, CBFA2/PEB2aB/AML1, and CBFA3/ment to one of these lineages. In vivo, the cues seem
PEBP2aC/AML2. Null mutation of Cbfa2 in mice wasto be provided primarily by the immediate cellular
embryonic lethal at midgestation due to hemorrhage inenvironment via cell±cell and cell±matrix interactions as
the central nervous system and disruption of fetal liverwell as by diffusible molecules. Findings from develop-
hematopoiesis. The null mutation Cbfb produced a simi-mental biology and cell culture studies suggest that
lar phenotype (Wang et al., 1996). Previous insitu hybrid-among the extracellular signals that can induce the os-
ization studies have reported that Cbfa3 is ubiquitouslyteoblastic phenotype are the bone morphogenetic pro-
expressed, whereas Cbfa1 is expressed in thymus andteins (BMPs), members of the TGFb superfamily. BMPs
testis butnot inbrain, lung, heart, spleen, liver, or kidney;were discovered as proteins extracted from bone and
bone was not reported in that study (Satake et al., 1995).are capable of inducing cartilage and bone formation
Four articles in this issue of Cell show strong expressionwhen injected subcutaneously, intramuscularly, or peri-
of Cbfa1 inosteogenic sites and implicate it as an essen-osteally into adult rats or other species (reviewed by
tial transcription factor in osteoblast differentiation, of-Reddi, 1997). BMPs play an important role in morpho-
fering significant new insight into the control of lineage-genesis and determination of the body axis (Graff, 1997)
specific differentiation in mesenchymal cells.and are expressed inmouse embryos at sitesof cartilage
Phenotype of Cbfa12/2 Miceand bone formation (Hogan, 1996). In the developing
Komori et al. (1997 [this issueof Cell]), on the assumptionlimb, BMP4 is induced by sonic hedgehog, originating
that Cbfa1 could be involved in T cell development,from the notochord, and participates in the signaling
deleted the gene in mice by homologous recombination.cascade required for limb morphogenesis. BMPs were
The phenotype is most interesting and was probably ashown to suppress myogenic or adipogenic expression
surprise to the authors. The homozygous Cbfa12/2 miceand to induce chondrogenic or osteogenic expression
died soon after delivery, cyanotic, due to inability toboth in multipotent and committed cell lines.
breathe. None were alive at the age of four weeks, how-These external cues trigger, in receptive cells, regula-
ever at gestational age 18.5 the distribution of embryostory pathways that lead to differentiation. The discovery
was as expected from Mendelian inheritance. On moreof MyoD and subsequently of myogenin and Myf-5 es-
detailed analysis, the homozygotes were smaller (z20%tablished the powerful paradigm of helix-loop-helix
(HLH) transcription factors, encoded by so-called ªmas- lower weight) and had shorter limbs but had all organs
and normal proportions. The most pronounced effectter genesº that are initially induced and start the cascade
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was a total lack of bone and retention of the partially of membranous bones, and delayed ossification of cra-
calcified cartilagenous skeleton. Both membranous nial bones, causing open anterior and posterior fonta-
bones of the skull and endochondral bone in the rest nelles, smaller parietal and interparietal cranial bones,
of the skeleton were absent. The skull was a thin layer and multiple Wormian bones (small bones in the su-
of fibrous connective tissue, the tibiae contained only tures). These are typical features of a human mutation
calcified cartilage, where bone is usually formed at this called cleidocranial dysplasia syndrome (CCD; Jensen,
age. Histochemical analysis showed absence of osteo- 1990). Most interestingly, an identical syndrome had
blastic cells and paucity and small size of osteoclasts, been produced in mice by gamma irradiation almost 20
the hematopoietically derived cells that normally remove years ago (Selby and Selby, 1978) and was recognized
calcified cartilage and bone. 10 years ago to be the mouse equivalent of the autoso-
Northern blot analysis of RNA extracted from bone in mal dominant human CCD syndrome (Sillence et al.,
homozygous Cbfa12/2 mice confirmed the extremely 1987). Genetic analysis of the mice heterozygous for the
low expression of genes associated with the osteoblas- CCD mutation in a C57BL/10 background crossed with
tic phenotype: alkaline phosphatase, osteopontin, and C3H, DBA/2J, and M. castaneus inbred strains, identi-
osteocalcin. Localization of Cbfa1 during development fied the mutation on chromosome 17 and, using DNA
by in situ hybridization documented its presence in re- markers, pointed to a disruption in the Cbfa1 gene.
gions destined for bone development. At gestational Thus, in addition to corroborating independently the
day 18.5, it was strongly expressed in osteoblasts and, essential role of Cbfa1 as a putative transcription factor
at lower levels, in thymus, testes, and liver, but no de- in osteoblast differentiation that cannot be compen-
fects in these organs were reported. Dilated blood ves- sated by another factor, these findings strongly impli-
sels and mineral deposits were observed in the vascular cated this gene in CCD. They also suggested haplotype
wall of the placenta, where no Cbfa1 mRNA was de- insufficiency for membranous but not endochondral
tected. RT±PCR analysis of RNA from calvaria-derived ossification, which explains the autosomal pattern of
cells, the skeleton, or skin, at gestational day 18.5 inheritance. The findings also drew attention to a strong
(d18.5), showed no differences between wild type and component of intramembraneous bone in clavicle devel-
homozygous Cbfa12/2 in the expression of osteogenic opment.
growth factors TGFbs, BMPs, IGFs and their receptors, Cleidocranial Dysplasia (CCD)
or in MCSF, required for osteoclast formation, consis- The human CCD syndrome (Jensen, 1990), an autosomal
tent with a downstream defect. dominant disorder with all the features described above
Indeed, rhBMP-2 up-regulation of the expression of in the Cbfa11/2 mice, plus supernumerary teeth, was
genes associated with the osteoblastic phenotype, alka- mapped to chromosome 6p21, where CBFA1 was local-
line phosphatase, and osteocalcin was significantly ized (Mundlos et al., 1995). Aware of the information
reduced in calvaria-derived cells from Cbfa12/2 d18.5
generated by Otto et al. (1997) in mice, Mundlos et al.
embryos. Similarly, the genes expressed in bone, osteo-
(1997 [this issue of Cell]) proceeded to examine whether
calcin, and osteopontin, estimated by in situ hybridiza-
CBFA1 is the culprit gene for CCD in humans. Sixty-two
tion, were suppressed in Cbfa12/2 mice. There was no
individuals, including 39 affected members, were testedmajor problem in hematopoiesis, except for an increase
for linkage to the 6p locus and all had a positive lodin the number of nucleated cells in the circulation, attrib-
score. CBFA1 was one of the genes identified within theuted to extramedullary hematopoiesis, caused by the
contig. Large deletions that included the CBFA1 locuslack of a normal marrow cavity.
were identified in three unrelated CCD patients. AnalysisIn a similar study, Otto et al. (1997 [this issue of Cell])
of CCD patients without chromosomal translocationindependently deleted the Cbfa1 gene in mice and had
found that three unrelated patients showed deletionsidentical findings in homozygous mutants: complete ab-
including the CBFA1 region and four additional familiessence of bone, smaller size, and neonatal death due to
had insertions, deletions, or mutations that inactivatedrespiratory failure. Using a 7 kb genomic sequence and
one allele or disrupted the runt domain of CBFA1. Ina reporter lacZ gene, Cbfa1 expression was docu-
summary, these data identified the lack of expressionmented at 9.5 days postcoitum (dpc) only in the noto-
of one allele of the CBFA1 gene as the basis of the CCDchord, at 10.5 dpc in mesoderm destined to become
syndrome in humans, fully consistent with the pheno-bone, at 11.5 dpc in maxillary and mandibular compo-
type of the Cbfa11/2 heterozygous mice. The only differ-nents of the first branchial arch as well as humerus, at
ence between the two species is the supernumerary12.5 dpc in ribs and vertebral bodies, in the developing
teeth in humans, the basis of which remains to be deter-bones of limbs and pelvic girdles, as well as in jaw and
mined.skull, thus corresponding closely to the earliest times
CBFA1 Stimulates Osteoblast-Specificand sites of osteogenesis. These authors also observed
Gene Expressionan increase in nucleated hematopoieticcells in thecircu-
The data reviewed so far strongly indicate that CBFA1lation and no abnormality in thymus development. Taken
plays a role in bone formation and, more specifically, intogether, these findings document by several methods
osteoblast differentiation. Its structure and role in otherthe absence of osteogenesis in Cbfa1-deficient mice
systems suggest that it acts as a transcription factor.and point to a role for this transcription factor at a stage
Direct evidence to that effect is provided by the fourththat precedes the expression of one of the earlier osteo-
study in this series by Ducy et al. (1997 [this issue ofblastic markers, alkaline phosphatase.
Cell]). Transcriptional regulation of osteoblast-specificAbnormalities in Heterozygous Mice
gene expression has been extensively studied in theIn addition, Otto et al. (1997) noticed certain abnormali-
promoter region of the human, rat, or mouse osteocalcinties in the Cbfa11/2 heterozygous mice: most promi-
nently hypoplasia of the clavicle, delayed development gene (Towler et al., 1994; Merriman et al., 1995), the
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marker for differentiated osteoblasts. Consistent with
this notion, OSE2-like elements were found in the pro-
moters of all examined genes expressed in osteoblasts:
type (I) collagen, osteopontin, bone sialoprotein, and
osteocalcin, in agreement with reduced expression of
these genes in Cbfa12/2 mice. These findings indicated
that Cbfa1 acting as a transcription factor is expressed
early during induction of osteoblast differentiation.
BMPs have been reported to induce the osteoblastic
phenotype in certain cell types, such as C3H10T1/2
cells. BMP7 induced Cbfa1 expression in these cells,
followed by the expression of osteocalcin and osteo-
pontin. In addition, 1,25(OH)2D3, previously shown to
suppress the mouse osteocalcin promoter, significantly
reduced the expression of Cbfa1 in primary mouse os-
teoblastic cells.
The ultimate test for the role of Cbfa1 as a crucial
Figure 1. Differentiation Pathways for Pluripotent Mesenchymal transcription factor that induces osteoblast-related
Cells genes is its ability to up-regulate these genes in
See text for details. nonosteoblastic or pre-osteoblastic cells. In calvaria-
derived nondifferentiated mouse MC3T3E-1 cells, tran-
best characterized ``bone-specific'' gene. Investigation sient transfection with a CMV promoter±driven Cbfa1
of osteoblast-specific cis-acting elements identified construct significantly up-regulated expression of a1(I)
unique regulatory DNAsequences in rat or mouse osteo- collagen, osteopontin, and osteocalcin. Similar effects
calcin promoters, including homeodomain-containing were observed in the nonosteoblastic C3H10T1/2 cells
protein binding sites and an E-box. One of these cis- and in skin fibroblasts. In the osteoblastic ROS 17/2.8
acting elements present in mouse and rat osteocalcin cells, Cbfa1 antisense mRNA down-regulated the ex-
promoters, called OSE2, was previously shown to confer pression of a1(I) collagen and osteopontin, suggesting
activity in osteoblasts to a heterologouspromoter and to a need for its constitutive expression in mature osteo-
bind a factor present only in osteoblast nuclear extracts blastic cells.
(Ducy and Karsenty, 1995). This factor is immunologi- This study by Ducy et al., which started with a different
cally related to CBFA transcription factors (Geoffroy et and more direct approach, documents the function of
al., 1995; Merriman et al., 1995). Based on this observa- Cbfa1 as a transcription factor that up-regulates the
tion, Ducy et al. (1997) cloned by low stringency hybrid- expression of osteoblast-related genes. Its conclusions
ization CBFA-like molecules from a mouse osteoblast are now strongly supported by loss-of-function evi-
cDNA library and isolated Cbfa1, which they named Osf2 dence presented in the three other related studies in
(osteoblast-specific transcription factor). By Northern this issue.
analysis, Cbfa1 mRNA was expressed in bone and in Together, these papers provide compelling evidence
osteoblasts, where it was 20 times more abundant than that Cbfa1 is an essential transcription factor required
in T lymphocytes. Histidine-tagged recombinant Cbfa1/ for osteoblast differentiation.
Osf2 protein binds to the nucleotide regulatory se- Open Questions
quence of the osteocalcin promoter and coexpression By analogy to myoblast differentiation, additional tran-
of Cbfa1/Osf2 in C3H10T1/2 cells stimulates by 70-fold scription factors, possibly linked via regulatory feedback
luciferase activity driven by six copies of the OSE2 regu- loops to CBFA1, may participate in expression of CBFA1
latory sequence upstream of the osteocalcin basal pro- and mutually regulate each other. This is consistent with
moter. This effect is abolished by a mutation in OSE2, its expression in thymocytes, liver, and testis, where it
which also abolishes the binding of the Cbfa1 protein. probably participates in the regulation of other genes.
These results show that Cbfa1/Osf2 stimulates osteo- Indeed, Ducy and Karsenty (1995) reported on a second
blast-specific transcription of the osteocalcin gene via regulatory region in the osteocalcinpromoter, and differ-
the OSE2 sequence. ent transcription factors that confer bone-specific ex-
CBFA1 Is a Transcription Activator pression to the a1 promoter of type I collagen, via a
of Osteoblast Differentiation distinct cis-acting element, were also recently reported
Consistent with the observations reviewed above, Ducy (Rossert et al., 1996).
et al. (1997) showed that in mouse development, expres- The studies presented here deal with very early osteo-
sion of Cbfa1 mRNA, examined by in situ hybridization, blast differentiation during embryogenesis, presumably
is present in mesenchymal condensation at 12.5 dpc from a multipotent mesenchymal cell. Bone formation
and at other sites prior to osteogenesis and osteocalcin in humans and other vertebrates occurs throughout life
expression. At 16 dpc, very strong expression was seen as part of continuous skeletal remodeling and occasion-
in facial bones and the bones of the skull, as well as in ally during fracture repair. The two processes differ from
the manubrium sternae, the sternebrae, and the hyoid each other. Fracture repair usually recapitulates the pro-
bone. No expression was detectable in chondrocytes. cess of endochondral bone formation, whereas remod-
This in vivo expression of Cbfa1 suggests that Cbfa1 eling recruits osteoblastic cells from a pool of committed
may regulate expression of early markers for osteoblast cells present in the bone marrow. It is of interest if the
cells participating in each of these processes expressdifferentiation, as well as expression of osteocalcin, a
Cell
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CBFA1, if they express it constitutively, or if it is induced
prior to osteoblastic differentiation by BMP or other fac-
tors, as observed during embryonic osteogenesis. In
other words, in the terminology of developmental biol-
ogy: what is the relationship of CBFA1 to osteoblast
commitment and to sustained phenotype expression?
Last but not least: how is the expression of CBFA1
regulated, could it be pharmacologically controlled to
stimulate bone formation therapeutically, for example
in osteoporosis?
In conclusion, following the myogenic and adipogenic
systems, we now have the beginning of significant mo-
lecular insights into the differentiation of the osteogenic
lineage (See Figure 1). Interestingly, each of these three
mesenchyme-derived cells are induced by transcription
factors belonging to completely different families, HLH
proteins, a nuclear receptor, and now a core binding
factor; family relations can be complicated but can be
resolved if patiently pursued.
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